发明名称 ACID-MODIFIED ARABINOGALACTAN PROTEIN COMPOSITION
摘要 An acid-modified arabinogalactan protein composition, having an arabinose-galactose ratio of less than 3.5:1 or less than 80 % of the arabinose:galactose ratio of the arabinogalactan protein component of the composition prior to acid modification, prepared from <i>Astragalus membranaceus</i>, especially from the roots of <i>Atragalus membranaceus</i>, is capable of reconstitution into an aqueous intravenously injectable formulation; and is useful for stimulating hematopoiesis, inducing the proliferation or maturation of megakaryocytes, stimulating the production of IL-1 beta , Il-6, TNF- alpha , IFN- gamma , GM-CSF, or G-CSF, stimulating the production or action of neutrophils, treating neutropenia, anemia, or thrombocytopenia, accelerating recovery from exposure (e.g. accidental or non-therapeutic exposure, as well as therapeutic exposure) to cytotoxic agents or radiation, treating cachexia, emesis, or drug withdrawal symptoms, or modifying biological responses or protecting hepatic cells in hepatitis B, in a mammal when intravenously administered to the mammal.
申请公布号 WO0202607(A2) 申请公布日期 2002.01.10
申请号 WO2001US20828 申请日期 2001.06.28
申请人 PHARMAGENESIS, INC.;AN, JINHUA;LEU, KAREN, S.;LENNOX, EDWIN, S.;MUSSER, JOHN, H. 发明人 AN, JINHUA;LEU, KAREN, S.;LENNOX, EDWIN, S.;MUSSER, JOHN, H.
分类号 A61K9/08;A61K31/715;A61K36/00;A61K36/48;A61K36/481;A61K38/00;A61K38/18;A61K38/19;A61K38/20;A61K38/22;A61K45/00;A61P1/08;A61P1/16;A61P7/00;A61P7/04;A61P7/06;A61P25/30;A61P31/00;A61P31/04;A61P31/10;A61P31/12;A61P35/00;A61P37/00;A61P37/02;A61P37/04;A61P39/00;A61P43/00;C07K1/12;C07K1/18;C07K14/415;C08B37/00 主分类号 A61K9/08
代理机构 代理人
主权项
地址